Frontiers in Psychiatry
December 6, 2023
Elliot Marseille, Manish Agrawal, Paul Thambi et al.
40 citations
Objective To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access. Methods Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician...
Journal of Military, Veteran and Family Health
December 1, 2023
Zachary Skiles, James R Dixon, Dan Friedrich et al.
The field of psychedelic-assisted psychotherapy and state-run psychedelic services will need to adequately train and certify facilitators to meet the anticipated demand for access. This article explores the role of peer support in the setting of medical and non-medical supervised psychedelic administration. Existing peer-support frameworks from both the psychedelic and the Veteran communities...
Life
November 8, 2023
Bruno Pires, Luana M. Rosendo, Ana Teresa Brinca et al.
15 citations
This review delves into the therapeutic applications of amphetamine-type stimulants such as lisdexamphetamine dimesylate, mixed amphetamine salts, 3,4-methylenedioxymethamphetamine (MDMA), dextroamphetamine, and phentermine. These compounds have been investigated for their potential in treating a range of psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), drug...
Journal of Sociology, Psychology & Religious Studies
November 6, 2023
Sarah Naher, Sarah Naher
1 citation
Mental illnesses pose social, economic, and health burdens worldwide. The increasing health burden and mental diseases pose the need for investigating other potential medications. The present review focuses on psychedelic medications. The Patient/Participant, Intervention, Outcomes, and Studies ([PICOS) protocol and the Preferred Reporting Items for Systematic Reviews (PRISMA) checklist guided...
Expert Review of Clinical Pharmacology
November 2, 2023
Fabrizio Schifano, Alessandro Vento, Norbert Scherbaum et al.
30 citations
Clinicians should be regularly informed about the range of NPS and their medical, psychobiological and psychopathological risks both in the acute and long term. Future research should focus on an integrative model in which pro-drug websites' analyses are combined with advanced research approaches, including computational chemistry studies so that in vitro and in vivo preclinical studies of...
Frontiers in Psychiatry
October 27, 2023
Aviv Weinstein
3 citations
There is increased risk of psychosis associated with cannabis use disorder and the interaction of THC with dopamine neurotransmission is complex. It is important to investigate the recovery from cannabis-induced psychosis and its effects on the brain’s dopamine neurotransmission. This study was to evaluate dopamine receptor D 2 availability in the striatum (caudate/putamen) in recently...
bioRxiv (Cold Spring Harbor Laboratory)
October 23, 2023
Ryan J. Rakoczy, Grace N. Runge, Abhishek K. Sen et al.
preprint
ABSTRACT Demand for more efficacious antidepressants, particularly those with a rapid onset of action, has resulted in a reevaluation of psychedelic drugs for their therapeutic potential. Several tryptamines found in psilocybin-containing ‘magic’ mushrooms share chemical similarities with psilocybin, and early work suggests they may also share receptor targets. However, few studies have...
Frontiers in Pharmacology
October 2, 2023
Victor P Acero, Emily S Cribas, Kevin D Browne et al.
20 citations
There has recently been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. Despite promising efficacy observed in some clinical trials, the full range of biological effects and mechanism(s) of action of these compounds...
Current Psychiatry Reports
October 1, 2023
Aaron Wolfgang, Charles W Hoge
15 citations
This review discusses the current and projected landscape of psychedelic-assisted therapy (PAT), with a focus on clinical, legal, and implementation considerations in Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. 3,4-Methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted therapy have shown promising outcomes in efficacy, safety, tolerability, and...
Drug and Alcohol Review
September 1, 2023
Joseph J Palamar
5 citations
It is largely unknown whether adverse effects experienced from recreational drug use affect willingness to use again. This study determined whether adverse effects from select party drugs affect reported willingness to use again in the next month among a high-risk population-people who attend electronic dance music parties at nightclubs or dance festivals. Adults (age ≥ 18) entering...